SCHEMBL4507697

SCHEMBL4507697

C#Cc1ccc2nc(-c3c(-c4ccccc4)noc3C)cn2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 6/20 0.48
PTGS1 P23219 4/20 0.48
MAPT P10636 6/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 4/20 0.44
KMT2A Q03164 2/20 0.44
HPGD P15428 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TP53 P04637 1/20 0.44
PKM P14618 1/20 0.44
TSHR P16473 1/20 0.44
CDK5 Q00535 1/20 0.44
CDK5R1 Q15078 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ALDH1A3 P47895 3/20 0.42
SLC2A1 P11166 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4486783 0.89 ALDH1A3 (0.53) PTGS2PTGS1MAPTTDP1L3MBTL1
SCHEMBL4488025 0.87 PTGS2 (0.46) PTGS2PTGS1MAPTTDP1L3MBTL1
SCHEMBL4501838 0.86 NPC1 (0.61) PTGS2PTGS1MAPTTDP1L3MBTL1
SCHEMBL4503190 0.84 PTGS2 (0.46) PTGS2PTGS1MAPTTDP1L3MBTL1
SCHEMBL4509374 0.82 PTGS2 (0.51) PTGS2PTGS1MAPTTDP1L3MBTL1
SCHEMBL4486580 0.82 PTGS2 (0.51) PTGS2PTGS1MAPTTDP1L3MBTL1
SCHEMBL4501121 0.82 RAB9A (0.60) PTGS2PTGS1MAPTTDP1L3MBTL1
SCHEMBL4502951 0.82 PTGS2 (0.51) PTGS2PTGS1MAPTTDP1L3MBTL1
SCHEMBL4493095 0.82 PTGS2 (0.51) PTGS2PTGS1MAPTTDP1L3MBTL1
SCHEMBL4490855 0.81 PTGS2 (0.55) PTGS2PTGS1MAPTTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7585874-B2 Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2009-09-08 US disclosed
EP-1979350-A1 ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE VIA GABA RECEPTORS F.HOFFMANN-LA ROCHE AG (CH) 2008-10-15 EP disclosed
US-20070179178-A1 Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
WO-2007082806-A1 ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER’S DISEASE VIA GABA RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179178-A1 Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives GABRA5, GABRA4, GABRA1 PTGS2 3313/4885PTGS1 2316/4885MAPT 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.